CMG Pharmaceutical Co., Ltd. (058820.KQ)
KRW 2470.0
(0.2%)
KRW 2470.0
(0.2%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 18.78 Billion KRW | 1431.76% |
| 2022 | 1.22 Billion KRW | -50.68% |
| 2021 | 2.48 Billion KRW | 6.05% |
| 2020 | 2.34 Billion KRW | 114.58% |
| 2019 | -16.07 Billion KRW | -32.9% |
| 2018 | -12.09 Billion KRW | -239.66% |
| 2017 | -3.56 Billion KRW | -100.02% |
| 2016 | -1.78 Billion KRW | 18.17% |
| 2015 | -2.17 Billion KRW | 67.4% |
| 2014 | -6.67 Billion KRW | 65.28% |
| 2013 | -19.21 Billion KRW | 0.0% |
| 2012 | - KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 23.74 Billion KRW | 89.59% |
| 2024 Q1 | 17.6 Billion KRW | -6.28% |
| 2023 Q3 | 14.3 Billion KRW | 13.69% |
| 2023 Q4 | 18.78 Billion KRW | 31.35% |
| 2023 FY | 24.87 Billion KRW | 1002.16% |
| 2023 Q1 | 117.65 Million KRW | -90.41% |
| 2023 Q2 | 12.57 Billion KRW | 10591.33% |
| 2022 Q3 | 3.13 Billion KRW | 8.99% |
| 2022 Q2 | 2.87 Billion KRW | 5.78% |
| 2022 Q1 | 2.71 Billion KRW | 9.22% |
| 2022 Q4 | 1.22 Billion KRW | -60.83% |
| 2022 FY | 2.25 Billion USD | 153.12% |
| 2021 Q3 | 2.55 Billion KRW | 3.55% |
| 2021 FY | -4.24 Billion USD | 43.74% |
| 2021 Q2 | 2.46 Billion KRW | 5.15% |
| 2021 Q4 | 2.48 Billion KRW | -2.64% |
| 2021 Q1 | 2.34 Billion KRW | 0.05% |
| 2020 Q4 | 2.34 Billion KRW | 5.19% |
| 2020 FY | -7.55 Billion USD | 52.61% |
| 2020 Q1 | -9.15 Billion KRW | 43.07% |
| 2020 Q2 | 2.2 Billion KRW | 124.08% |
| 2020 Q3 | 2.22 Billion KRW | 1.14% |
| 2019 Q2 | -3.86 Billion KRW | 23.67% |
| 2019 Q1 | -5.06 Billion KRW | 58.15% |
| 2019 Q4 | -16.07 Billion KRW | 14.52% |
| 2019 FY | 2.19 Billion USD | -6276.57% |
| 2019 Q3 | -18.8 Billion KRW | -386.76% |
| 2018 Q3 | -12.33 Billion KRW | -283.06% |
| 2018 FY | -249.95 Million USD | -35.43% |
| 2018 Q4 | -12.09 Billion KRW | 1.91% |
| 2018 Q2 | -3.21 Billion KRW | -23.23% |
| 2018 Q1 | -2.61 Billion KRW | 26.65% |
| 2017 Q4 | -3.56 Billion KRW | 58.01% |
| 2017 FY | -184.56 Million USD | -110.02% |
| 2017 Q1 | -1.07 Billion KRW | 39.74% |
| 2017 Q2 | -8.55 Billion KRW | -697.83% |
| 2017 Q3 | -8.48 Billion KRW | 0.9% |
| 2016 Q4 | -1.78 Billion KRW | 22.39% |
| 2016 Q2 | -1.86 Billion KRW | 17.24% |
| 2016 Q1 | -2.25 Billion KRW | -3.81% |
| 2016 Q3 | -2.29 Billion KRW | -22.74% |
| 2016 FY | -87.88 Million USD | 64.12% |
| 2015 Q1 | -5.08 Billion KRW | 23.77% |
| 2015 Q4 | -2.17 Billion KRW | 64.8% |
| 2015 FY | -244.94 Million USD | 41.61% |
| 2015 Q3 | -6.18 Billion KRW | -225.66% |
| 2015 Q2 | -1.89 Billion KRW | 62.69% |
| 2014 Q3 | -7.59 Billion KRW | 36.92% |
| 2014 Q1 | -18.36 Billion KRW | 4.44% |
| 2014 FY | -419.46 Million USD | -29.78% |
| 2014 Q4 | -6.67 Billion KRW | 12.16% |
| 2014 Q2 | -12.04 Billion KRW | 34.43% |
| 2013 FY | -323.2 Million USD | -0.2% |
| 2013 Q1 | 13.46 Billion KRW | 0.0% |
| 2013 Q2 | -9.59 Billion KRW | -171.3% |
| 2013 Q3 | -2.25 Billion KRW | 76.56% |
| 2013 Q4 | -19.21 Billion KRW | -754.09% |
| 2012 Q4 | - KRW | 0.0% |
| 2012 FY | -322.55 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 18.96 Billion KRW | 0.934% |
| Celltrion Pharm, Inc. | 142.81 Billion KRW | 86.847% |
| Huons Global Co., Ltd. | 13.26 Billion KRW | -41.608% |
| DongKook Pharmaceutical Co., Ltd. | 44.19 Billion KRW | 57.496% |
| Enzychem Lifesciences Corporation | -9.81 Billion KRW | 291.416% |
| Humedix Co., Ltd. | -77.54 Billion KRW | 124.223% |
| Boditech Med Inc. | -31.92 Billion KRW | 158.836% |
| EuBiologics Co., Ltd. | 4.88 Billion KRW | -284.804% |
| FutureChem Co.,Ltd | -4.93 Billion KRW | 480.97% |
| Huons Co., Ltd. | 73.9 Billion KRW | 74.585% |
| BNC Korea Co., Ltd. | -67.65 Billion KRW | 127.766% |
| AptaBio Therapeutics Inc. | -12.08 Billion KRW | 255.469% |